Back to Archived Journals » Current Biomarker Findings » Volume 2

Molecular biomarkers of glioblastoma: current targets and clinical implications

Authors Koji Y, Mizoguchi M, Hata, Amano, Nakamizo, Sasaki

Received 26 June 2012

Accepted for publication 7 August 2012

Published 4 September 2012 Volume 2012:2 Pages 63—76

DOI https://doi.org/10.2147/CBF.S25590

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Koji Yoshimoto, Masahiro Mizoguchi, Nobuhiro Hata, Toshiyuki Amano, Akira Nakamizo, Tomio Sasaki

Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Abstract: Recent genome-wide analysis of glioblastoma has revealed various molecular alterations that can be candidate targets of biomarker findings. Although glioblastomas are diagnosed on the basis of their histopathological morphological features, it has been demonstrated that molecular heterogeneity among glioblastomas is prominent, and pathological diagnosis cannot always predict the clinical behavior of the tumor. Thus, molecular biomarkers have been anticipated to provide prognostic and predictive significance. Given that recent medical treatment strategies have been progressing toward individualized therapy and many targeted drugs have been investigated, the identification of molecular biomarkers in glioblastoma will be of considerable therapeutic importance. Although the clinical implications of these biomarkers must be determined in prospective studies, a growing number of candidate biomarkers have been investigated. In this review, the recent molecular alterations in glioblastoma that may be significant biomarkers are summarized; particular focus is on loss of heterozygosity on chromosome 10, epidermal growth factor receptor (EGFR)/EGFR variant III expression, alterations in the receptor tyrosine kinase-phosphatidylinositol 3-kinase pathway, isocitrate dehydrogenase mutation, epigenetic alterations, gene expression profiling, and microRNA expression.

Keywords: EGFRvIII , IDH, global gene expression profiling

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]